{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=9",
    "query": {
      "condition": "Mild to Moderate Alzheimer's Disease",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 199,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T18:26:07.886Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02036645",
      "title": "SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild-Moderate Alzheimer's Disease",
        "Healthy Elderly"
      ],
      "interventions": [
        {
          "name": "MEDI1814 for IV injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI1814 for Subcutaneous Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IV Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for Subcutaneous Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 77,
      "start_date": "2014-02-04",
      "completion_date": "2016-09-15",
      "has_results": true,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 10,
      "location_summary": "Glendale, California • Long Beach, California • Panorama City, California + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02036645"
    },
    {
      "nct_id": "NCT02754830",
      "title": "A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "LY3303560 - IV",
          "type": "DRUG"
        },
        {
          "name": "Saline Solution - IV",
          "type": "DRUG"
        },
        {
          "name": "LY3303560 - SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2016-04-25",
      "completion_date": "2018-07-10",
      "has_results": true,
      "last_update_posted_date": "2023-10-13",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02754830"
    },
    {
      "nct_id": "NCT05189210",
      "title": "GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild to Moderate Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "GV1001 Placebo",
          "type": "DRUG"
        },
        {
          "name": "GV1001 0.56mg",
          "type": "DRUG"
        },
        {
          "name": "GV1001 1.12mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GemVax & Kael",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 199,
      "start_date": "2022-10-05",
      "completion_date": "2025-04-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 12,
      "location_summary": "Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Adventura",
          "state": "Florida"
        },
        {
          "city": "Greenacres City",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05189210"
    },
    {
      "nct_id": "NCT00153010",
      "title": "An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "NS 2330 (Tesofensine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 430,
      "start_date": "2003-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-10-29",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 80,
      "location_summary": "Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00153010"
    },
    {
      "nct_id": "NCT02386306",
      "title": "Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "GC021109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GliaCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 39,
      "start_date": "2015-02",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-02-03",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 5,
      "location_summary": "Long Beach, California • Deerfield Beach, Florida • Hallandale, Florida + 2 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02386306"
    },
    {
      "nct_id": "NCT05686044",
      "title": "A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Buntanetap/Posiphen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annovis Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 351,
      "start_date": "2023-04-01",
      "completion_date": "2024-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 54,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 42 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05686044"
    },
    {
      "nct_id": "NCT00766363",
      "title": "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Central Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "EVP-6124 (0.1 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "EVP-6124 (0.3 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "EVP-6124 (1.0 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "Comparator: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FORUM Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 49,
      "start_date": "2008-10",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2012-04-20",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00766363"
    },
    {
      "nct_id": "NCT00574132",
      "title": "Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Bapineuzumab 0.5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "DRUG"
        },
        {
          "name": "Bapineuzumab 1.0 m/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "JANSSEN Alzheimer Immunotherapy Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "50 Years to 88 Years"
      },
      "enrollment_count": 1331,
      "start_date": "2007-12",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 219,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 170 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574132"
    },
    {
      "nct_id": "NCT00151333",
      "title": "Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "SRA-333",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2005-02",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2009-09-04",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00151333"
    },
    {
      "nct_id": "NCT01527916",
      "title": "Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "donepezil",
          "type": "DRUG"
        },
        {
          "name": "ABT-126",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 438,
      "start_date": "2012-02",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-11-19",
      "last_synced_at": "2026-11-19T18:26:07.886Z",
      "location_count": 8,
      "location_summary": "Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more",
      "locations": [
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Elk Grove Village",
          "state": "Illinois"
        },
        {
          "city": "Staten Island",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527916"
    }
  ]
}